In Brief: J&J Eyes Earlier Lines Of Therapy For Tecvayli After Second Phase III Win
Clinical Data Readout: J&J’s BCMA-targeting bispecific antibody Tecvayli reduced the risk of disease progression or death by 71% in patients with relapsed/refractory multiple myeloma who have received one to three prior lines of therapy.
Scrip - January 15, 2026

Bio Usawa Scores Ghanian Approval For Its Lucentis Biosimilar
Bio Usawa continues to expand access to its Formycon/Bioeq-partnered ranibizumab biosimilar, landing its second approval in Africa.
Generics Bulletin - January 15, 2026

FDA’s Yim On What The Future Holds For Biosimilars In 2026
Speaking at a pre-J.P Morgan science summit, Sarah Yim – director of the US FDA’s Office of Therapeutic Biologics and Biosimilars – set out the FDA’s plans to achieve further progress on biosimilars both domestically and internationally in 2026.
Generics Bulletin - January 15, 2026

J.P. Morgan: Sandoz Foresees ‘Golden Decade’ Despite Near-Term Lack Of LOEs
Sandoz says the next ten years will provide a “golden decade” of off-patent competition from which it is uniquely placed to benefit – despite a relative lack of fresh loss-of-exclusivity opportunities in 2026 and 2027.
Generics Bulletin - January 15, 2026

Haleon Adds Microbiome Extensions To UK Centrum VMS Brand
Haleon looks to tap into the growing UK gut health category with Centrum Multibiotics Complete and Centrum Multibiotics Daily.
HBW Insight - January 15, 2026

J.P. Morgan: Novo Rallies As Lilly Advances In Oral GLP-1 Battleground
CEOs of both the market leaders for weight-loss injections spoke at length during the J.P. Morgan Healthcare conference about the market potential for pills, which are gearing up to become the next frontier in the obesity treatment space.
Scrip - January 15, 2026

Deals Shaping The Industry, December 2025
An interactive look at pharma, medtech and diagnostics deals made during December 2025. Data courtesy of Biomedtracker.
In Vivo - January 15, 2026

Valneva Mulls Asia Shield To US Headwinds, Considers Shigella Candidate Options
While the regulatory environment for vaccines sours in the US, Valneva tells Scrip it is mulling an Asia hub and finalizing a strategy - that includes partnerships - for its marketed and pipeline products. Could it consider India or China as a new regional center?
Scrip - January 15, 2026

BioBytes: AI-Related Deals In Q4 2025
AI-related deal activity in the fourth quarter of 2025 brought a broad mix of financing rounds, acquisitions and strategic collaborations.
In Vivo - January 15, 2026

Novo Nordisk Foundation Backs Europe Start-Ups To Bring More Breakthroughs To Market
Europe produces world-class science, but lags behind other regions in translating discoveries into groundbreaking innovations that create jobs and drive economic growth. A new fund from the owners of Novo Nordisk hopes to change that.
Scrip - January 15, 2026

Q&A: Proposed US Sunscreen Monograph Addition Shines Light On Questions As Well As Opportunities
“Our sense is that companies are currently focused on timing, scope and execution. For example, knowing when a final order might issue … We also imagine that formulators are scrutinizing the proposed list of permitted combinations, the 6% cap, and the permitted dosage forms,” say ArentFox Schiff att
HBW Insight - January 15, 2026

Optimism Reigns At J.P. Morgan Despite A Lack Of Deals
The mood in San Francisco was focused and upbeat as investors and dealmakers continue to anticipate a busy year ahead for M&A.
Scrip - January 15, 2026

J.P. Morgan Notebook: Big Pharmas Weigh In On Vaccines, AI And MFN
Sanofi's Paul Hudson on vaccine M&A, BMS's Lenkowsky on its MFN deal, Gilead's business development priorities, BI prepares for obesity/MASH readouts, GSK talks AI and AstraZeneca buys Modella AI, plus more from day three of J.P. Morgan.
Scrip - January 15, 2026